Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
For more information about Leidos Biomedical Research Inc., please visit our webpage at http://www.leidosbiomed.com/
The Molecular Characterization Laboratory (MoCha) is part of Leidos Biomedical Research’s Clinical Research Directorate (CRD) at the Frederick National Laboratory for Cancer Research. The MoCha Laboratory is responsible for providing high-level research in support of the NCI-Cancer Diagnostics Program (CDP) within the Division of Cancer Treatment and Diagnosis (DCTD). MoCha is charged with the development and application of genomic assays for use in medical research and diagnostics for DCTD-sponsored national extramural clinical trials.
The Senior Scientist will: 1) provide genomic assay support to DCTD projects including the Patient Derived Xenograft Models (PDM) project, 2) conduct and supervise scientific projects , 3) design or propose experiments to understand biological pathways relevant in cancer drug development, 4) perform assay development and validation, 5) exercise independent judgment in developing and/or modifying methods and techniques for solving scientific problems, 6) perform data analysis and quality control evaluations, 7) perform formal reporting of research data, including presentations and/or scientific publications, and 8) maintain knowledge of the most recent literature and scientific presentations relevant to projects. This position is located in Frederick, MD.
This work involves the use of potentially hazardous chemicals, biological or radiological materials or may be located in areas where such materials are used, the use of personal protective equipment and strict adherence to safety protocols and standard operating procedures will be required.
PhD in a related discipline from an accredited college or university according to the Council for Higher Education Accreditation (CHEA)
Foreign degrees must be evaluated for U.S. equivalency
A minimum of five (5) years of competent, innovative research experience
Strong knowledge of molecular biology and skills in the analysis of human specimens
Expertise in the field of oncology
Attention to detail and ability to identify and successfully address unexpected results
Ability to deliver high quality results in a timely manner
Proven ability to manage projects and staff as well as work independently
Ability to work within a highly matrix team environment
Ability to write and orally present data and project updates in a clear and effective manner
Must have first authorships on peer-reviewed publications, attendance and presentation experience at national meetings
Ability to preside over meetings showing leadership qualities, independence with sound ideas, vision and ability to remain focused on the mission/project
Experience with diagnostic assay development
Familiarity with human clinical studies where biomarker assays have been employed
Strong technical skills and knowledge in genomic assay development
Experience in cancer genomics and/or signaling pathway analysis
Familiarity with clinical oncology studies or other protocol-driven clinical research